Physician profile
Patrice B Evers
NPI 1124168182
$976.63
in general payments reported to CMS, 2019-2025
16 companies · $366 in 2025
The $366 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.24 · 2020: $32.06 · 2021: $39.50 · 2022: $98.40 · 2023: $215 · 2024: $162 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $180.04 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $166.23 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $159.34 | 2022-2025 | Penmenvy, Bexsero |
| Genzyme Corporation | $108.14 | 2023 | |
| Sanofi Pasteur INC. | $90.36 | 2019-2025 | |
| Cranial Technologies, INC | $42.00 | 2024-2025 | Doc Band |
| Cipher Pharmaceuticals US LLC | $33.63 | 2025 | Natroba, Spinosad |
| Sobi, INC | $29.66 | 2021-2022 | |
| Kyowa Kirin, INC. | $29.38 | 2025 | |
| Ironshore Pharmaceuticals INC. | $24.77 | 2019 | |
| Tris Pharma INC | $23.36 | 2025 | Onyda Xr |
| Seqirus USA INC | $22.03 | 2025 | Flucelvax |
| Phadia US INC. | $19.50 | 2024 | Immunocap |
| Millicent US INC | $17.41 | 2025 | Femlyv |
| Sanofi-Aventis U.S. LLC | $17.01 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $13.77 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrice Evers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.